Navigation Links
Mylan Announces Proposed Senior Notes Private Placement
Date:5/4/2010

PITTSBURGH, May 4 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it intends to privately place $1.0 billion in aggregate principal amount of senior notes due 2017 and 2020.  The net proceeds from the private placement of the notes are expected to be used by Mylan to prepay a portion of its outstanding term loans.

The notes will be sold only to qualified institutional buyers in the United States in reliance on Rule 144A under the Securities Act of 1933, and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act.  The proposed issuance of the notes will not be registered under the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.  This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor shall there be any sale of securities mentioned in this press release in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Mylan

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a spe
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Receives Approval for Generic Version of Zyban(R)
2. Mylan Receives Approval for Generic Version of Flomax(R)
3. Mylan Schedules First Quarter 2010 Financial Results Conference Call and Live Webcast
4. Mylan Receives Approval for Generic Version of Actigall(R)
5. Mylan Awarded NABP-VAWD Accreditation for Its Primary North American Distribution Facility
6. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
7. Mylan Receives Approval for Generic Version of GoLytely(R)
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
10. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based ... spinal cord injury (SCI) treatment with their novel Neuro-Spinal ... tissue regrowth in the spinal cord area when cells ... approved polymer, the scaffold ultimately breaks down to water ... body. NVIV has recently attracted significant investor attention with ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... policy , , ROCHESTER, Minn., ... use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, ... alcohol. The results of the study are published in the December ... , VIDEO ALERT: Additional audio and video ...
... VICL ) announced today the receipt of a $1.0 ... Merck,s planned initiation of a Phase I clinical trial of ... is based on Vical,s DNA gene delivery technology and encodes ... separate license agreement. , , ...
Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... in the war on asthma symptom control could be a ... that Mom and Dads leeriness towards their childrens asthma medications ... health risks that outweigh the benefits might explain to ... children with the wheezing, coughing and trouble-breathing disease do not ...
... Consultech Strengthens Omnicom,s Presence in China,s Growing ... ... Omnicom Group Inc.,("Omnicom") (NYSE: OMC ), the leading global ... Services,division ("DAS"), a majority ownership interest in Consultech, a leading,healthcare ...
... The American,Psychiatric Association (APA) applauds the U.S. Food and ... led to the,approval of a new treatment for two ... the approvals are a result of the federal,Best Pharmaceuticals ... that leads to this kind of approval, given that ...
... 180 day shared exclusivity on the product, ... announced today that the Company has received tentative ... manufacture and market,Galantamine Hydrobromide Tablets, 4mg (base), 8mg ... treatment of mild to moderate dementia of,the Alzheimer,s ...
... the best drug treatment for their disease, because family doctors ... in the Archives of Disease in Childhood. , Around ... disease prompts up to a third of children aged between ... researchers used national data to calculate the number of prescriptions ...
... in This Region,Deep Commitment to this Market Evidenced in Opening of ... ... and PHILADELPHIA, Sept. 3 Rohm,and Haas Company (NYSE: ROH ... in India to meet,growing demand for its environmentally advanced products and ...
Cached Medicine News:Health News:Parents' perceptions can hamper kids' asthma care, study finds 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 3Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis 2Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Rohm and Haas Expands in India 2Health News:Rohm and Haas Expands in India 3Health News:Rohm and Haas Expands in India 4
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Ideal for short scleral tunnel and trabecular meshwork incisions...
30 Pre-formed and razor sharp...
Medicine Products: